University of Kentucky Research Foundation

Markos Leggas

Jurgen Rohr

Oleg Tsodikov

Joseph M Eckenrode

Prithiba Mitra

Abhisek Mandal

Caixia Hou

Jon Scott Thorson

David S Watt

Daniel C Scott

Vitaliy M Sviripa

Chunming Liu

Wen Zhang

Jianjun Zhang

Khaled Attia Shaaban Mahmoud

Jhong-Min Chen

Yinan Zhang

Yang Liu

Mithramycin (MTM) short side chain ketone (SK) derivatives and MTM short side chain diketone (SDK) derivatives are provided. The MTM SK and MTM SDK derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM SK and MTM SDK derivatives have increased selectively toward ETS transcription factor.

Mithramycin derivatives having increased selectivity and anti-cancer activity

Compounds described herein are mithramycin (MTM) oxide (OX) derivatives and MTM Hydrazine (HY) derivatives. These compounds are useful for treatment of cancers and neuro-diseases.

Mithramycin oxime derivatives having increased selectivity and anti-cancer activity

Mithramycin side chain carboxylic acid (MTM-SA) derivative are provided, which include a substituted amino acid derivative, a substituted amino acid dipeptide derivative, or an unsubstituted dipeptide derivative. The MTM-SA derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM-SA derivatives have increased selectively toward ETS transcription factor.

Halogenated phenylethynyl-substituted heterocycles that possess either an N-alkylamino or N,N-dialkylamino group attached to the heterocycle or halogenated phenylethynyl-substituted benzenes that a nitrogen-containing heterocycle attached to the benzene inhibit the proliferation cancer cells and are useful antineoplastic agents.

Phenylethynyl-substituted benzenes and heterocycles for the treatment of cancer

Mithramycin derivatives and their pharmaceutically acceptable salts are disclosed. The mithramycin derivatives can be used in the treatment of Ewing sarcoma or other cancer or neuro-disease associated with an aberrant erythroblast transformation-specific transcription factor.

Semi-synthetic mithramycin derivatives with anti-cancer activity

Growing community of inventors

Lexington, KY, United States of America

Markos Leggas